Actively Recruiting
Oral Immunonutrition Therapy to Reduce Acute Toxicity After Neoadjuvant Chemoradiotherapy Pancreatic Cancer Patients
Led by Sun Yat-sen University · Updated on 2024-12-17
98
Participants Needed
2
Research Sites
57 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A prospective, single-arm clinical trial is conducted to investigate the role of oral immunonutrion in reducing acute toxicity after neoadjuvant chemoradiotherapy among pancreatic cancer patients.
CONDITIONS
Official Title
Oral Immunonutrition Therapy to Reduce Acute Toxicity After Neoadjuvant Chemoradiotherapy Pancreatic Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically confirmed pancreatic ductal epithelial malignant tumors
- Resectable pancreatic cancer treated with neoadjuvant chemoradiotherapy, or nonresectable locally advanced pancreatic cancer treated with neoadjuvant or radical chemoradiotherapy
- Nutritional Risk Screening 2002 (NRS2002) score of 3 or higher and Patient-Generated Subjective Global Assessment (PG-SGA) performance status B
- Age 18 years and older
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Expected survival time more than 3 months
- History of antineoplastic therapy
You will not qualify if you...
- Known allergy or intolerance to any component of the investigational Oral Immunonutrition
- Use of Oral Immunonutrition within one month prior to enrollment
- Tumor compressing the major duodenal papilla, or presence of jaundice or acute pancreatitis
- Contraindications for antineoplastic therapy such as coronary heart disease, cerebral infarction, cerebral hemorrhage, or other serious diseases
- Liver, kidney, or blood coagulation function failure
- Presence of hemopathy
- Active infections
- Other primary tumors
- Other medical diseases seriously affecting nutritional status
- Any other factors deemed by the investigator that may make the participant ineligible
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
2
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Actively Recruiting
Research Team
W
Weiwei Xiao
CONTACT
L
Liping Chen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here